The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
REGULATORY
MHLW Panel Begins Discussions on Revision of Basic Policy for Blood Products
A health ministry panel on March 20 started discussions on revising the “basic policy to improve the safety and ensure the stable supply of blood products” established under the Blood Law. Major topics include measures to strengthen domestic manufacturers, optimize…
To read the full story
Related Article
- Panel Approves Revision to Basic Blood Product Policy; Change to Take Effect Next April
October 24, 2023
- Draft Revision of Basic Blood Product Policy OK’ed, to Be Finalized by March-End
September 27, 2023
- 3 Japan Manufacturers of Plasma-Derived Products Call for Changes in Export Rules: PAFSC Committee
June 13, 2023
- Japan Panel to Draw Up Revision Outline for Basic Blood Products Policy by September, Eyes Profitability Improvement
April 26, 2023
REGULATORY
- CEFP Discusses Social Security Reform Timeline, No Surprises for Pharma Measures
December 6, 2023
- Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
- 500 Billion Yen-Plus Annual Savings Expected from Generic Switches: Reiwa Rincho
December 5, 2023
- Japan Eyes Stronger OTC Sales Restrictions Due to Drug Abuse
December 4, 2023
- Reliance on Drug Price Cuts to Pool Financial Resources Must End: LDP Lawmakers
December 4, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…